---
title: "Vabysmo (faricimab-svoa), all indications: Access and coverage questions"
description: "Access and coverage questions on Vabysmo (faricimab-svoa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Access and billing, Access support, Cost and coverage, Prior authorization, and Patient support. Questions: What are the NDC numbers for Vabysmo? What is the J-code for Vabysmo? How many J2777 units are billed for one Vabysmo dose? Is the JZ modifier required when billing Vabysmo? 26 further questions follow. 30 questions quoted from 15 sources."
canonical: "https://www.evicenter.com/medical-information/vabysmo/access-and-coverage"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa), all indications: Access and coverage questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)  
Indication pages: [Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)

## Access and billing

<a id="vabysmo-ndc"></a>

### What are the NDC numbers for Vabysmo?

> “Drug: NDC*
> Note: Payer requirements regarding 
> use of a 10-digit or 11-digit NDC  
> may vary. Both formats are listed 
> here for your reference.
> 10-digit
> 11-digit
> 50242-096-01 
> 50242-0096-01
> VABYSMO (6 mg [0.05 mL of 120 mg/mL solution])  
> in a single-dose vial with sterile 5-micron, blunt transfer filter needle 
> (18-gauge × 1½-inch)
> 50242-096-03
> 50242-0096-03
> VABYSMO (6 mg [0.05 mL of 120 mg/mL solution])  
> in a single-dose vial
> 50242-096-06
> 50242-0096-06
> VABYSMO (6 mg [0.05 mL of 120 mg/mL solution])  
> in a single-dose prefilled syringe with a sterile injection filter needle 
> (30-gauge × ½-inch, Extra Thin Wall)”

Source: [VABYSMO: Sample Coding: Neovascular (Wet) Age‑related Macular Degeneration (nAMD), page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf#page=1)

> “*Some payers may require the vial NDC instead of the carton. Please check the individual payer’s NDC billing policy for billing direction.”

Source: [VABYSMO: Sample Coding: Neovascular (Wet) Age‑related Macular Degeneration (nAMD), page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf#page=1)

> “VABYSMO is supplied in the following presentations: 
>
> NDC NUMBER  
> CARTON TYPE 
> CARTON CONTENTS 
> 50242-096-06 
> Prefilled Syringe 
> one 6 mg (0.05 mL of 120 mg/mL solution) single-
> dose prefilled glass syringe, in a sealed tray 
>
> one sterile injection filter needle (30-gauge x ½ 
> inch, 0.30 mm x 12.7 mm, Extra Thin Wall) 
>
> one Prescribing Information 
> 50242-096-01 
> Vial 
> one 6 mg (0.05 mL of 120 mg/mL solution) single-
> dose glass vial 
>
> one sterile 5-micron blunt transfer filter needle (18-
> gauge x 1½ inch, 1.2 mm x 40 mm) 
>
> one Prescribing Information”

Source: [VABYSMO: Prescribing information, page 24, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=24)

Note: The first two passages are from the Genentech sample coding sheet for wet AMD; the third is the How Supplied table of the Prescribing Information. The coding sheet (marked 07/24) lists a third NDC, 50242-096-03, a single-dose vial without the filter needle, which the How Supplied table of the Prescribing Information (revised 4/2026) does not list.

<a id="vabysmo-j-code"></a>

### What is the J-code for Vabysmo?

> “Drug: HCPCS
> J2777
> Injection, faricimab-svoa, 0.1 mg”

Source: [VABYSMO: Sample Coding: Neovascular (Wet) Age‑related Macular Degeneration (nAMD), page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf#page=2)

> “These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.”

Source: [VABYSMO: Dosing & Administration in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/dosing-and-administration-namd.html#:~:text=These%20codes%20are%20not%20all%2Dinclusive%3B,for%20any%20service%20or%20item.)

<a id="vabysmo-billing-units"></a>

### How many J2777 units are billed for one Vabysmo dose?

> “BILLABLE UNITS
> Bill 60 units with J2777 for the 6-mg single-dose of VABYSMO. Payers might have different preferences for billing for VABYSMO. Check with your 
> local payers for specific billing unit information.”

Source: [VABYSMO: Sample Coding: Neovascular (Wet) Age‑related Macular Degeneration (nAMD), page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf#page=2)

<a id="vabysmo-jz-modifier"></a>

### Is the JZ modifier required when billing Vabysmo?

> “HCPCS: Modifier*
> JZ
> Zero drug amount discarded/not administered to any patient”

Source: [VABYSMO: Sample Coding: Neovascular (Wet) Age‑related Macular Degeneration (nAMD), page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf#page=2)

> “The JZ modifier is required on claims for all single-dose containers or single-use drugs when no drug is discarded/administered to any patient as of July 1, 2023.  
> For more information on the JZ modifier, visit CMS.gov.”

Source: [VABYSMO: Sample Coding: Neovascular (Wet) Age‑related Macular Degeneration (nAMD), page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/coding/VABYSMO-Billing-Coding-for-wet-AMD.pdf#page=2)

<a id="vabysmo-specialty-distributors"></a>

### How can practices buy Vabysmo (specialty distributors)?

> “Genentech has contracted with a network of authorized specialty distributors to service practices choosing to purchase VABYSMO through the buy and bill model. Customers can purchase VABYSMO through authorized specialty distributors and wholesalers that have made a commitment to product integrity. These partners have agreed to distribute only products purchased directly from Genentech and not to distribute VABYSMO through secondary channels.
>
> Distributors for Federal Accounts
>
> Distributor	Telephone	Fax	Web Orders
> Besse Medical (Cencora)	800-543-2111	800-543-8695	www.besse.com/home
> Dakota Drug	866-210-5887	763-421-0661	www.dakdrug.com/ContactUs.aspx
> DMS Pharmaceutical	877-788-1100	847-518-1105	www.dmspharma.com/contact-us
>
> Distributors for Hospitals
>
> Distributor	Telephone	Fax	Web Orders
> Besse Medical (Cencora)	800-543-2111	800-543-8695	www.besse.com/home
> BioCareSD	800-304-3064	N/A	biocare-us.com
> CuraScript SD (Priority Health)	877-599-7748	800-862-6208	curascriptsd.com/Contact-Us
> McKesson Plasma and Biologics (MPB)	877-625-2566	N/A	www.mckesson.com/Pharmaceutical-Distribution/Plasma-Biologics/
> Morris & Dickson	800-388-3833	318-524-3096	www.morrisdickson.com/products/specialty/
>
> Distributors for Physician Offices and Federally Qualified Health Centers
>
> Distributor	Telephone	Fax	Web Orders
> Besse Medical (Cencora)	800-543-2111	800-543-8695	www.besse.com/home
> BioCareSD	800-304-3064	N/A	biocare-us.com
> CuraScript SD (Priority Health)	877-599-7748	800-862-6208	curascriptsd.com/Contact-Us
> McKesson Specialty Health (McKesson Specialty Care Distribution Corporation)	800-482-6700	N/A	www.mckesson.com/specialty/
> Metro Medical (Cardinal Health)	800-768-2002	615-256-4194	www.metromedicalorder.com
>
> Distributors for Authorized Specialty Pharmacies
>
> Distributor	Telephone	Fax	Web Orders
> Besse Medical (Cencora)	800-543-2111	800-543-8695	www.besse.com/home
> BioCareSD	800-304-3064	N/A	biocare-us.com
> CuraScript SD (Priority Health)	877-599-7748	800-862-6208	curascriptsd.com/Contact-Us
> McKesson Specialty Health (McKesson Specialty Care Distribution Corporation)	800-482-6700	N/A	www.mckesson.com/specialty/
>
> Distributors for Puerto Rico
>
> Distributor	Telephone	Fax	Web Orders
> Besse Medical (Cencora)	800-543-2111	800-543-8695	www.besse.com/home
> Cardinal Health Puerto Rico	787-625-4200	N/A	cardinalhealth.pr/”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=Genentech%20has%20contracted%20with%20a,cardinalhealth.pr%2F)

This passage is in a collapsed section of the page; select: Distributors for Physician Offices and Federally Qualified Health Centers, Distributors for Hospitals, Distributors for Federal Accounts, then Distributors for Puerto Rico

> “VABYSMO can be procured through a select list of specialty distributors.  
> Please visit Genentech-Pro.com to view the latest list.”

Source: [VABYSMO: guide, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/injection-ordering-guide.pdf#page=2)

Note: The distributor tables are those on the VABYSMO page of genentech-pro.com captured November 13, 2026, which the VABYSMO Injection Ordering Guide names as the source of the latest list.

<a id="vabysmo-buy-and-bill"></a>

### How does buy and bill work for Vabysmo?

> “With buy and bill, the practice purchases the medication in advance, then bills the patient’s health insurance plan for reimbursement. The practice is responsible for storing and handling the drug, as well as collecting the patient’s co-pay for both the drug and its administration. With buy and bill, practices can maintain a stock of the drug, giving them the flexibility to treat patients when clinically appropriate.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=With%20buy%20and%20bill%2C%20the,treat%20patients%20when%20clinically%20appropriate.)

## Access support

<a id="vabysmo-samples"></a>

### Are Vabysmo samples available?

> “VABYSMO Sampling Program
> If you are interested in requesting VABYSMO samples, 
> contact your Therapeutic Area Manager (TAM).”

Source: [VABYSMO: resources, page 9, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-access-and-reimbursement.pdf#page=9)

Note: From the VABYSMO access and reimbursement guide (marked 11/25), captured November 13, 2026.

<a id="vabysmo-spoilage-replacement"></a>

### Can spoiled Vabysmo be replaced?

> “Replacing spoiled medicine
> To submit a request for replacement of spoiled product 
> or to obtain additional information about the Genentech 
> Spoilage Replacement Program:
> •	 Visit gene.com/customerservice and select “Returns” 
> •	 Call the Genentech Ophthalmology Support Line at  
> (833) EYE-GENE/(833) 393-4363 and press 2”

Source: [VABYSMO: resources, page 9, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-access-and-reimbursement.pdf#page=9)

Note: From the VABYSMO access and reimbursement guide (marked 11/25), captured November 13, 2026.

<a id="vabysmo-specialty-pharmacies"></a>

### Which specialty pharmacies dispense Vabysmo?

> “Pharmacy	Telephone	Fax	Web Orders
> AcariaHealth	800-511-5144	877-329-4605	www.acariahealth.com
> Accredo	888-608-9010	877-329-4605	www.accredo.com
> AleraCare	888-209-8874	N/A	www.aleracare.com/
> Alivia Specialty Pharmacy (Puerto Rico)	787-979-2023	N/A	www.aliviahealth.com/specialty-pharmacy
> BioMatrix Specialty Pharmacy	877-337-3002	N/A	www.biomatrixsprx.com/
> BioPlus Specialty Pharmacy	866-514-8082	800-269-5493	www.bioplusrx.com
> Birdi (aka Elixir, formerly Envision)	877-437-9012	N/A	www.elixirsolutions.com/
> CareMed Pharmaceutical Services (Sorkins Rx Ltd)	877-227-3405	877-542-2731	www.caremedps.com
> CenterWell Specialty Pharmacy (formerly Humana Specialty Pharmacy)	800-486-2668	N/A	www.centerwellpharmacy.com/
> CVS Specialty	800-237-2767	800-323-2445	www.cvsspecialty.com
> Kalamazoo Long Term Care Pharmacy	269-388-4850	269-388-4870	kltcpharmacy.com/
> Prime Therapeutics (Magellan)	855-457-0007	N/A	https://www.primetherapeutics.com/
> MC-RX (Medical Centre Specialty Pharmacy)	855-828-1484	N/A	www.mc-rx.com/
> Nufactor	800-323-6832	N/A	www.nufactor.com/
> Optima Infusion Pharmacy (Puerto Rico)	787-883-5959	787-883-6042	www.optimahealthpr.com/
> Optum Specialty Pharmacy	855-427-4682	877-342-4596	specialty.optumrx.com/
> Perform Specialty	855-287-7888	844-489-9565	www.performspecialty.com/
> Pruitt Health Pharmacy Services	678-533-6459	N/A	pruitthealth.com/microsite/facilityid504
> Publix Specialty Pharmacy	855-797-8254	N/A	www.publix.com/pharmacy/pharmacy-services/specialty
> Reliance Rx (Specialty Pharmacy Management)	716-929-1000	716-532-7360	www.reliancerxsp.com/
> Special Care Pharmacy (Puerto Rico Only)	787-783-8579	787-783-2951	specialcarepr.com
> Specialty Pharmacy Service (SPS) (Puerto Rico Only)	787-704-2025	787-704-2027	www.spscaguas.com
> Value Specialty Pharmacy (Value Drug Company)	800-252-3786	814-944-3146	www.valuedrugco.com
> Walgreens Specialty Pharmacy	888-782-8443	N/A	www.walgreens.com/topic/pharmacy/specialty-pharmacy.jsp
> Walmart Specialty Pharmacy	877-453-4566	866-537-0877	www.walmart.com/cp/4101489
>
> Note: Pharmacies primarily serving the patients of particular health systems or health plans are not included in this list.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=Specialty%20Pharmacies-,Pharmacy,not%20included%20in%20this%20list.)

This passage is in a collapsed section of the page; select: Specialty Pharmacies

> “We work with these authorized distributors and specialty pharmacies to provide VABYSMO to patients and the prescribers.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=We%20work%20with%20these%20authorized,to%20patients%20and%20the%20prescribers.)

> “Genentech does not influence or advocate the use of any one specialty distributor or specialty pharmacy. We make no representation or guarantee of service or coverage of any item.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=and%20the%20prescribers.-,Genentech%20does%20not%20influence%20or%20advocate%20the%20use%20of%20any,or%20coverage%20of%20any%20item.)

Note: The list is the one on the VABYSMO page of genentech-pro.com captured November 13, 2026.

<a id="vabysmo-benefits-investigation"></a>

### How do I start a Vabysmo benefits investigation?

> “How to Start a Benefits Investigation
>
> Get started with enrollment by following the steps below.
>
> Option 1: Submit online
>
> If your practice has a registered account for My Patient Solutions, you can get started by logging into your account.
>
> Go to My Patient Solutions
>
> Don't have an account?
>
> Launch Quick Enroll
>
> Your patient is required to complete the Patient Consent Form. You can either upload their Patient Consent Form as part of your application or have your patient submit the form via fax, text or e-submit.
>
> Option 2: Print & fax or text
>
> Step 1: Print one of the Patient Consent Forms below for your patient to complete.
>
> Patient Consent Form (English)
> Patient Consent Form (Spanish)
>
> Step 2: Print and complete the Prescriber Service Form below.
>
>
> Prescriber Service Form
>
> Step 3: Submit the completed forms via fax or text.
>
>
> Send via fax to (866) 480-7762
> Text a photo of the form to 650-877-1111
>
> Both forms are required. We must have both the Patient Consent Form and the Prescriber Service Form before we can help you.
>
> What to expect next:
>
> The request will be processed within five business days upon receipt of both required forms.
> Your office will be contacted to discuss any next steps.”

Source: [VABYSMO: Helpful Resources for Your Practice, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/helpful-resources-for-your-practice.html#:~:text=How%20to%20Start%20a%20Benefits,to%20discuss%20any%20next%20steps.)

This passage is in a collapsed section of the page; select: How to Start a Benefits Investigation

<a id="vabysmo-appeals"></a>

### How do I appeal a Vabysmo insurance denial?

> “If your patient’s health insurance plan has issued a denial, your Genentech Ophthalmology Access Solutions specialist can provide resources as you prepare an appeal submission, as per your patient’s plan requirements. 
>
> If a plan issues a denial: 
>
> The denial should be reviewed, along with the health insurance plan’s guidelines to determine what to include in your patient’s appeal submission.
> Your Genentech Ophthalmology Access Solutions specialist has local payer coverage expertise and can help you determine specific requirements for your patient.
>
> A sample appeal letter and additional considerations are available on the Practice Forms & Documents page.
>
> Appeals cannot be completed or submitted by Genentech on your behalf.”

Source: [VABYSMO: Helpful Resources for Your Practice, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/helpful-resources-for-your-practice.html#:~:text=If%20your%20patient%E2%80%99s%20health%20insurance,by%20Genentech%20on%20your%20behalf.)

<a id="vabysmo-reverification"></a>

### What is Vabysmo benefits reverification?

> “When a medical treatment is authorized by the patient’s insurance plan for a limited period of time, it will generally require reverification of coverage for continued treatment. Genentech Ophthalmology Access Solutions can help you obtain reverification for your patients. To opt into reverification, please select the check box on the Prescriber Service Form.
>
>
> If the patient’s health insurance plan denies the request for reverification, your practice may file an appeal on behalf of your patient.”

Source: [VABYSMO: Helpful Resources for Your Practice, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/helpful-resources-for-your-practice.html#:~:text=When%20a%20medical%20treatment%20is,on%20behalf%20of%20your%20patient.)

<a id="vabysmo-specialty-pharmacy"></a>

### Does insurance require a specialty pharmacy for Vabysmo?

> “VABYSMO Access Solutions works with specialty pharmacies (SPs) to help patients receive their medicines. 
>
> An SP may provide the following services: 
>
> Reimbursement resources 
> Clinical services to support patients throughout their treatment 
> The ability to manage the specialty handling and shipping needs linked with many specialty therapies 
>
> You can work with your preferred SP or contact VABYSMO Access Solutions to learn which SP the patient’s health insurance plan requires.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=VABYSMO%20Access%20Solutions%20works%20with,patient%E2%80%99s%20health%20insurance%20plan%20requires.)

> “If your patient's insurance plan has a mandated or preferred specialty pharmacy”

Source: [VABYSMO: Helpful Resources for Your Practice, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/helpful-resources-for-your-practice.html#:~:text=If%20your%20patient%27s%20insurance%20plan%20has%20a%20mandated%20or%20preferred%20specialty%20pharmacy)

> “Specialty Pharmacy (SP) Distribution Support
> Determine if a pharmacy is required by your patient’s insurance
>
> Support pharmacy exceptions, if needed
> Identify which specialty pharmacies distribute VABYSMO”

Source: [VABYSMO: Case Managers, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/case-managers.html#:~:text=Specialty%20Pharmacy%20%28SP%29%20Distribution%20Support,which%20specialty%20pharmacies%20distribute%20VABYSMO)

## Cost and coverage

<a id="vabysmo-price-wac"></a>

### What is the Vabysmo price (WAC)?

> “VABYSMO Vial
> Description
> VABYSMO (6 mg [0.05 mL of 120 mg/mL solution]) 
> in a single-dose vial with sterile 5-micron, blunt 
> transfer filter needle (18-gauge × 1½-inch) 
> Product 
> number
> 10-digit NDC: 50242-096-01 
> 11-digit NDC: 50242-0096-01
> WAC
> $2,483.74”

Source: [VABYSMO: guide, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/injection-ordering-guide.pdf#page=1)

> “VABYSMO Prefilled Syringe (PFS)
> Description
> VABYSMO (6 mg [0.05 mL of 120 mg/mL solution]) 
> in a single-dose prefilled syringe with a sterile 
> injection filter needle (30-gauge × ½-inch, Extra 
> Thin Wall) 
> Product 
> number
> 10-digit NDC: 50242-096-06
> 11-digit NDC: 50242-0096-06
> WAC
> $2,483.74”

Source: [VABYSMO: guide, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/injection-ordering-guide.pdf#page=1)

> “NDC=National Drug Code; WAC=wholesale acquisition cost.”

Source: [VABYSMO: guide, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/injection-ordering-guide.pdf#page=1)

Note: The figures are the wholesale acquisition cost per vial or prefilled syringe printed in the VABYSMO Injection Ordering Guide (marked 08/26), captured November 13, 2026. The guide does not state an effective date for the WAC.

<a id="vabysmo-cost-commercial"></a>

### How much does Vabysmo cost with commercial insurance?

> “As little as $0 co-pay for eligible commercially-insured patients”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=As%20little%20as%20%240%20co%2Dpay%20for%20eligible%20commercially%2Dinsured%20patients)

> “Up to $1,000 for administration and $15,000 for drug per calendar year**”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=Up%20to%20%241%2C000%20for%20administration%20and%20%2415%2C000%20for%20drug%20per%20calendar%20year%2A%2A)

> “The Programs are not available to patients whose prescriptions are reimbursed under any federal state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Programs.”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=The%20Programs%20are%20not%20available,be%20eligible%20for%20the%20Programs.)

> “The total patient out-of-pocket cost is dependent on the patient’s health insurance plan.”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=The%20total%20patient%20out%2Dof%2Dpocket%20cost,the%20patient%E2%80%99s%20health%20insurance%20plan.)

> “After reaching the maximum Programs’ benefit amounts, the patient will be responsible for all remaining out-of- pocket expenses.”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=After%20reaching%20the%20maximum%20Programs%E2%80%99,all%20remaining%20out%2Dof%2D%20pocket%20expenses.)

<a id="vabysmo-copay-enrollment"></a>

### How do patients enroll in the Vabysmo copay program?

> “To get started, call (855) 218-5307 or visit EyeOnCopay.com.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=To%20get%20started%2C%20call%20%28855%29%20218%2D5307%20or%20visit%20EyeOnCopay.com.)

> “Eligibility criteria and benefit limits apply. Not valid for patients using federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=Eligibility%20criteria%20and%20benefit%20limits,list%20of%20Terms%20and%20Conditions.)

> “Call (855) 218-5307 from 9 a.m. to 8 p.m. ET, Monday–Friday”

Source: [VABYSMO: resources, page 12, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-access-and-reimbursement.pdf#page=12)

> “Enroll patients directly using the Prescriber Service Form  
> and Patient Consent Form”

Source: [VABYSMO: resources, page 12, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-access-and-reimbursement.pdf#page=12)

<a id="vabysmo-copay-program"></a>

### Is there a Vabysmo copay assistance program?

> “Help With Costs for VABYSMO
>
> With the Genentech Ophthalmology Co-pay Program, eligible patients with commercial insurance could pay as little as $0 per treatment. Co-pay assistance of up to $15,000 is provided per calendar year.
>
> Your patient may be eligible if they:
>
> Have been prescribed VABYSMO for an FDA-approved indication
> Are 18 years of age or older, or have a caregiver or legally authorized person to manage the patient's co-pay assistance
>
> Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
>
> Reside and receive treatment in the U.S. or U.S. Territories
>
> Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
>
> Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=Help%20With%20Costs%20for%20VABYSMO,Medigap%2C%20Medicaid%2C%20VA%2C%20DoD%2C%20TRICARE%29)

This passage is in a collapsed section of the page; select: Genentech Ophthalmology Co-Pay Program

<a id="vabysmo-administration-copay"></a>

### Does the Vabysmo copay program cover injection (administration) costs?

> “Help With Costs for Administration
>
> With the Genentech Ophthalmology Co-pay Program, eligible patients with commercial insurance could pay as little as $0 per VABYSMO injection. Co-pay assistance is provided up to $1,000 per calendar year.
>
> Your patient may be eligible if they:
>
> Have been prescribed VABYSMO for an FDA-approved indication
> Are 18 years of age or older, or have a caregiver or legally authorized person to manage the patient's co-pay assistance
> Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
>
> Reside and receive treatment in the U.S. or U.S. Territories
> Are not receiving assistance through any charitable organization for the same expenses covered by the program*
> Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)
> Do not reside or receive treatment in a restricted state (e.g. Massachusetts or Rhode Island)
>
> *Patients may use the Genentech Ophthalmology Co-Pay Program for their administration costs if they are receiving their treatment from the Genentech Patient Foundation.”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=Help%20With%20Costs%20for%20Administration,from%20the%20Genentech%20Patient%20Foundation.)

This passage is in a collapsed section of the page; select: Genentech Ophthalmology Co-Pay Program

<a id="vabysmo-medicare-copay"></a>

### Can Medicare patients use the Vabysmo copay program?

> “The Programs are not available to patients whose prescriptions are reimbursed under any federal, state, or government-funded insurance programs (included but not limited to Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs Programs) or where prohibited by law or by the patient's health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state or government-funded healthcare programs, the patient will no longer be eligible for the Programs.”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=The%20Programs%20are%20not%20available,be%20eligible%20for%20the%20Programs.)

This passage is in a collapsed section of the page; select: Genentech Ophthalmology Co-Pay Program

> “For patients who are not able to use the Genentech 
> Ophthalmology Co-pay Program, including those with 
> Medicare or Medicaid, Genentech Ophthalmology 
> Access Solutions offers referrals to independent  
> co-pay assistance foundations.”

Source: [VABYSMO: resources, page 13, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-access-and-reimbursement.pdf#page=13)

<a id="vabysmo-independent-foundations"></a>

### Which independent foundations may help pay for Vabysmo?

> “An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times and the type or amount of assistance available (if any) can vary by foundation.”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=An%20independent%20co%2Dpay%20assistance%20foundation,any%29%20can%20vary%20by%20foundation.)

On the page, select: Independent Co-pay Assistance Foundations

> “Macular Disease:
> Good Days from CDF
> Patient Access Network Foundation (PANF)
> The Assistance Fund, Inc.
> The HealthWell Foundation
> Retinal Disease: 
> Good Days from CDF
> Patient Access Network Foundation (PANF)”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=Macular%20Disease%3A,Patient%20Access%20Network%20Foundation%20%28PANF%29)

On the page, select: Independent Co-pay Assistance Foundations

> “Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help your patient.”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=Independent%20co%2Dpay%20assistance%20foundations%20have,might%20be%20able%20to%20help%20your%20patient.)

On the page, select: Independent Co-pay Assistance Foundations

Note: The foundation list is the one shown on the VABYSMO HCP financial assistance page captured November 13, 2026.

<a id="vabysmo-patient-foundation"></a>

### Is there a Vabysmo patient assistance program for free drug?

> “The Genentech Patient Foundation gives free VABYSMO to people who have been prescribed this medicine and don’t have insurance or that have financial concerns and meet certain eligibility criteria.
>
> Your patient may be eligible if their insurance coverage and income match one of these situations:
>
> Uninsured patients with incomes under $150,000
> Insured patients without coverage for VABYSMO with incomes under $150,000
> Insured patients with coverage for a Genentech medicine:
> With an out-of-pocket maximum set by their health insurance plan that exceeds 7.5% of their household income
> With household size and income within certain guidelines
>
>
> For any of these situations, add $25,000 for each extra person in households larger than 4 people.
>
> We encourage insured patients to try other financial assistance options before applying for help from the Genentech Patient Foundation, if possible.”

Source: [VABYSMO: Financial Assistance Options, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/assistance-options.html#:~:text=The%20Genentech%20Patient%20Foundation%20gives,Genentech%20Patient%20Foundation%2C%20if%20possible.)

This passage is in a collapsed section of the page; select: Genentech Patient Foundation

> “Call (888) 941-3331 to speak with a live Foundation Specialist.”

Source: [VABYSMO: Genentech Pro, captured 2026-11-13](https://www.genentech-pro.com/our-products/vabysmo.html#distribution-section:~:text=Call%20%28888%29%20941%2D3331%20to%20speak%20with%20a%20live%20Foundation%20Specialist.)

<a id="vabysmo-denial-free-drug"></a>

### Can patients get free Vabysmo after an insurance denial?

> “No. If the patient's health insurance plan denied coverage for VABYSMO (after submission of a Prior Authorization, if required), the patient can apply for help from the Genentech Patient Foundation. The patient does not need to send proof of the appeal to get help.”

Source: [VABYSMO: Financial Support FAQs, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/faqs.html#:~:text=No.%20If%20the%20patient%27s%20health,the%20appeal%20to%20get%20help.)

On the page, select: If the patient’s health insurance denies coverage, do I need to provide a proof of appeal for financial assistance?

<a id="vabysmo-insurance-coverage"></a>

### Is Vabysmo covered by insurance?

> “~85% of patients covered
>
> to start VABYSMO as their first branded treatment<sup>‖</sup>”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=~85%25%20of%20patients%20covered,VABYSMO%20as%20their%20first%20branded)

> “Coverage determined for VABYSMO vial based on Medicare Fee for Service and tracking of the largest payers for other books of business. Bevacizumab (not indicated for intraocular use) and biosimilars are excluded from the branded treatment category. Specific coverage may vary for individuals and plans. Data as of January 2025.”

Source: [VABYSMO: Treatment for nAMD, DME, & RVO, captured 2026-11-13](https://www.vabysmo-hcp.com/#:~:text=Coverage%20determined%20for%20VABYSMO%20vial,Data%20as%20of%20January%202025.)

> “Select Payer Policies 
> (as of June 2026)”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “<sup>§</sup>In certain circumstances, payers mandate step therapy with bevacizumab (not indicated for intraocular use).”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

Note: The 85% figure is from the VABYSMO HCP home page captured November 13, 2026, with data as of January 2025; the step therapy passage is from the manufacturer's Coverage At-a-Glance document, select payer policies as of June 2026.

<a id="vabysmo-medicare-coverage"></a>

### Is Vabysmo covered by Medicare and Medicare Advantage?

> “Select Payer Policies 
> (as of June 2026)”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “Covered first line for Medicare FFS, Anthem*,  
> UnitedHealthcare Commercial and HCSC<sup>†</sup>”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “Department of 
> Defense (DoD)
> Medicare Fee-for-
> Service (FFS)
> Veterans Affairs (VA)
> Covered first line with no PA or step edits required:”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “Medicare Advantage Policy<sup>‡</sup>”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “UnitedHealthcare Policy 
> nAMD: Covered after 
> double step through  
> 1. bevacizumab<sup>§</sup> 
> 2. aflibercept 2 mg  
> or aflibercept 8 mg or 
> aflibercept-ayyh”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “Aetna Policy 
> nAMD and RVO: Covered  
> after double step through  
> 1. bevacizumab 
> 2. ranibizumab-nuna<sup>§</sup> 
> or aflibercept 2 mg or aflibercept 8 mg  
> or aflibercept-ayyh”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Humana Policy 
> Covered after a single step 
> through bevacizumab<sup>§</sup>”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “<sup>‡</sup>PA criteria varies by plan and is subject to change; providers are responsible for complying with requirements.”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Individual plan policies may vary; coverage is not guaranteed. Information provided is for reference only and does not replace 
> benefits verification.”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

Note: From the manufacturer's Coverage At-a-Glance table (select payer policies as of June 2026), captured November 13, 2026. Medicare fee-for-service (FFS), Veterans Affairs, and Department of Defense are listed together under the third passage's heading; the document's text layer prints the three labels before the heading. The UnitedHealthcare and Aetna passages are those payers' Medicare Advantage policies; Humana lists the same policy for its commercial and Medicare Advantage plans.

## Prior authorization

<a id="vabysmo-step-therapy"></a>

### Do insurers require step therapy with bevacizumab before Vabysmo?

> “<sup>§</sup>In certain circumstances, payers mandate step therapy with bevacizumab (not indicated for intraocular use).”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Centene Policy 
> Covered after a single step 
> through bevacizumab<sup>§</sup>”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Humana Policy 
> Covered after a single step 
> through bevacizumab<sup>§</sup>”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Cigna Policy 
> Covered after a single 
> step through bevacizumab<sup>§</sup> 
> or  
> Covered with no step 
> edits for MDs with 
> repackaged bevacizumab<sup>§</sup> 
> safety concerns”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Aetna Policy 
> Covered after double 
> step through 
> 1. bevacizumab<sup>§</sup> 
> 2. ranibizumab-nuna”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “UnitedHealthcare Policy 
> nAMD: Covered after 
> double step through  
> 1. bevacizumab<sup>§</sup> 
> 2. aflibercept 2 mg  
> or aflibercept 8 mg or 
> aflibercept-ayyh”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “Individual plan policies may vary; coverage is not guaranteed. Information provided is for reference only and does not replace 
> benefits verification.”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

Note: Each payer passage is a cell of the manufacturer's Coverage At-a-Glance table (select payer policies as of June 2026), captured November 13, 2026. Centene and Humana list the same single-step policy for commercial and Medicare Advantage plans; the Cigna and Aetna passages are their commercial policies; the UnitedHealthcare passage is its Medicare Advantage policy for nAMD.

<a id="vabysmo-step-back-appeal"></a>

### Is there a Vabysmo appeal letter for a bevacizumab step-back denial?

> “Sample Avastin Step Back Appeal Letter for VABYSMO<sup>®</sup> (faricimab-svoa)”

Source: [VABYSMO: Sample Avastin Step Back Appeal Letter for VABYSMO, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-sample-avastin-step-back-appeal.pdf#page=1)

> “● You may use this appeal letter template when a prior authorization has been denied for 
> a patient switching to VABYSMO due to an Avastin step-back payer policy requirement”

Source: [VABYSMO: Sample Avastin Step Back Appeal Letter for VABYSMO, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-sample-avastin-step-back-appeal.pdf#page=1)

> “● Please note that using the information in this sample letter does not guarantee that the 
> health plan will provide coverage and reimbursement for the Genentech product. It is not 
> intended to be a substitute for, or influence on, the independent medical judgment of the 
> health care professional”

Source: [VABYSMO: Sample Avastin Step Back Appeal Letter for VABYSMO, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-sample-avastin-step-back-appeal.pdf#page=1)

Note: Avastin is the brand name of bevacizumab.

<a id="vabysmo-prior-authorization"></a>

### Does Vabysmo need prior authorization?

> “Genentech Ophthalmology Access Solutions can conduct a benefits investigation (BI) which can determine:
>
> If treatment is covered
> If treatment is denied
> If a prior authorization or pre-determination is required*
> If your patient's insurance plan has a mandated or preferred specialty pharmacy
>
> *If your patient’s request for a prior authorization is not granted, your Genentech Ophthalmology Access Solutions specialist can work with you to determine your next steps.”

Source: [VABYSMO: Helpful Resources for Your Practice, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/helpful-resources-for-your-practice.html#:~:text=Genentech%20Ophthalmology%20Access%20Solutions%20can,to%20determine%20your%20next%20steps.)

> “Department of 
> Defense (DoD)
> Medicare Fee-for-
> Service (FFS)
> Veterans Affairs (VA)
> Covered first line with no PA or step edits required:”

Source: [VABYSMO: coverage, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=1)

> “<sup>‡</sup>PA criteria varies by plan and is subject to change; providers are responsible for complying with requirements.”

Source: [VABYSMO: coverage, page 2, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/vabysmo-hcp/pdfs/vabysmo-payer-coverage.pdf#page=2)

> “Prior Authorizations (PAs)
> Help you identify if a PA is necessary
>
> Offer resources as you obtain PAs for your patients
> Provide PA forms”

Source: [VABYSMO: Case Managers, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/case-managers.html#:~:text=Prior%20Authorizations%20%28PAs%29,Provide%20PA%20forms)

Note: The second passage is from the manufacturer's Coverage At-a-Glance table (select payer policies as of June 2026), captured November 13, 2026; its three payer labels (Medicare fee-for-service, Veterans Affairs, Department of Defense) precede their shared heading in the document's text. The PA criteria footnote (‡) is attached to the table's Commercial and Medicare Advantage columns.

<a id="vabysmo-letter-medical-necessity"></a>

### Is there a letter of medical necessity template for Vabysmo?

> “Letter of Medical Necessity
>
> This guide provides tips to help you draft a letter of medical necessity. A sample letter is also included for your reference.”

Source: [VABYSMO: Forms and Documents, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/practice-forms-and-documents.html#:~:text=Necessity%20and%20Appeal-,Letter%20of%20Medical%20Necessity,also%20included%20for%20your%20reference.)

> “Including a Letter of Medical Necessity when submitting a PA can explain the clinical 
> decision-making behind the choice of a specific therapy, potentially helping patients access treatment.”

Source: [VABYSMO: Tips for Drafting a Letter of Medical Necessity, page 1, captured 2026-11-13](https://www.vabysmo-hcp.com/content/dam/gene/accesssolutions/pdfs/letter-medical-necessity/Considerations-for-Composing-a-Letter-of-Medical-Necessity.pdf#page=1)

## Patient support

<a id="vabysmo-case-managers"></a>

### What do Vabysmo Access Solutions case managers do?

> “When your patient is enrolled in Genentech Ophthalmology Access Solutions, a qualified Case Manager will work with both of you throughout your journey with VABYSMO.
>
> Case Managers are not healthcare professionals and cannot provide medical advice.
>
> Case Managers can help with:
> Enrollment
>
> Answer questions you or your patients may have throughout the enrollment process
>
>
> Patient Assistance
>
> Help identify potential financial and other assistance for eligible patients
>
>
> Benefits Investigations (BIs)
>
> Walk your patients through the results of their BIs and help them understand next steps
>
>
> Prior Authorizations (PAs)
> Help you identify if a PA is necessary
>
> Offer resources as you obtain PAs for your patients
> Provide PA forms
> Specialty Pharmacy (SP) Distribution Support
> Determine if a pharmacy is required by your patient’s insurance
>
> Support pharmacy exceptions, if needed
> Identify which specialty pharmacies distribute VABYSMO
> Automatic VABYSMO Benefits Reverification
> Reverify patients' benefits prior to their next scheduled treatment
>
> Coordinate with patients, practices and treatment sites (if applicable) to schedule the next treatment”

Source: [VABYSMO: Case Managers, captured 2026-11-13](https://www.vabysmo-hcp.com/financial-support/case-managers.html#:~:text=When%20your%20patient%20is%20enrolled,to%20schedule%20the%20next%20treatment)

<a id="vabysmo-access-support-phone"></a>

### What is the phone number for Vabysmo access support?

> “Need more help? Contact Genentech Ophthalmology Access Solutions
>
> Call (833) EYE-GENE/(833) 393-4363 (Mon.–Fri., 6AM–5PM PST), except major holidays”

Source: [VABYSMO: Helpful Resources for Your Practice, captured 2026-11-13](https://www.vabysmo-hcp.com/resources/helpful-resources-for-your-practice.html#:~:text=Need%20more%20help%3F%20Contact%20Genentech,6AM%E2%80%935PM%20PST%29%2C%20except%20major%20holidays)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): All indications](https://www.evicenter.com/medical-information/vabysmo)
- [Indication](https://www.evicenter.com/medical-information/vabysmo/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vabysmo/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/vabysmo/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vabysmo/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vabysmo/storage-and-supply)
